Is ARDX Worth Buying in 2026?

Ardelyx, Inc.

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether Ardelyx, Inc. (ARDX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: 50-day MA is rising (+0.88% over 10 days); strong 1-year return of +52.8%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-9.9%). Currently 33.8% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

ARDX is trading below its 200-day MA ($6.14) — a key warning sign the longer-term trend is under pressure. An RSI of 32.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +52.8% compares to +24.4% for SPY (beat the market by 28.4%). The current 33.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $15,275 today
vs. S&P 500 (SPY) — same period beat market by 28.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($6.14)
Above 50-day MA ($6.18)
RSI(14) neutral zone (30–70) — currently 32.8
Positive return (+52.8%)
!Within 10% of period high (−33.8%)
Period Range $5.56
$3.49 $8.40
RSI (14) 32.8
0 · OversoldOverbought · 100

Key Metrics

Price$5.56
Period Return+52.8%
Period High$8.40
Period Low$3.49
Drawdown−33.8%
MA-50$6.18
MA-200$6.14
RSI (14)32.8
Avg Volume (30d)3.9M
vs. SPYbeat by 28.4%
Return Rank#337 of 1245

Trade ARDX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers